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Abstract
TGF-β is a pluripotent cytokine that can have both tumor suppressing and tumor promoting
effects on epithelial cells.  It is unclear what determines when TGF-β and its signaling pathway
act predominantly as a tumor suppressor pathway or as a tumor-promoter pathway and whether
TGF-ß can have both classes of effects concurrently on a cell.  We investigated the effect of
TGF-β on anoikis in colorectal cancer cell lines sensitive to TGF-_-mediated growth inhibition
to determine if the context of the cells could be one of the factors that would affect whether
TGF-β exerts tumor suppressor or oncogene activity on colon cancer cells.  We observed
variable effects of TGF-_ on anoikis in these cell lines, even though they all are growth-inhibited
by TGF-β. Thus, we show that TGF-β has variable effects on anoikis in colon cancer cell lines
that likely reflects the effects of concurrent gene mutations in the cancer cells and the activation
state of the signaling pathways controlled by these genes.
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The Transforming Growth Factor-β (TGF-β) superfamily comprises a large number of
cytokines that regulate tissue homeostasis and development through the regulation of
fundamental processes such as cell proliferation, differentiation, motility and programmed cell
death.  TGF-β has been shown to not only play a central role in development and normal organ
function, but also to affect many pathological processes such as cirrhosis, nephrosclerosis, and
tumorigenesis (reviewed in (Elliott and Blobe 2005; Massague 1998)).
There is considerable genetic evidence that the TGF-_ signaling pathway is a tumor suppressor
pathway in colon epithelial cells.  Much of this evidence is derived from studies in human colon
cancers demonstrating inactivating mutations in genes encoding proteins involved in TGF-_ signal
transduction, including SMAD4 (Hahn et al. 1996; Schutte et al. 1996), SMAD2 (Eppert et al. 1996),
and TGFBR2 (Grady et al. 1999; Parsons et al. 1995).  Additional evidence for a tumor suppressor
role for the TGF-_ signaling pathway is derived from studies of mouse models of cancer.
Overexpression of TGF-_1 in mammary epithelial cells and skin keratinocytes suppresses the
development of carcinomas (Pierce et al. 1995).  Expression of a dominant-negative TGFBR2
(DNIIR) in mammary epithelial cells increases the incidence of mammary tumors (Gorska et al.
2003; Gorska et al. 1998).  Furthermore, invasive colon tumors develop in Smad3-/-, Tgfb1-/-, and
ApcΔ716 Smad4+/- mice, and mice that lack TGFBR2 in the colon, Fabp4xat-132 Cre Tgfbr2flx/flx mice,
are more susceptible to azoxymethane-induced colon neoplasms than are mice with intact TGFBR2
in the colonic epithelium (Biswas et al. 2004; Engle et al. 1999; Engle et al. 2002; Takaku et al.
1998; Zhu et al. 1998).
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However, the role of TGF-β signaling during the process of tumor development is complex.
Its effects appear to be context-dependent and can even be paradoxical.  Results from in vitro
and in vivo model systems as well as from epidemiological studies have made evident that the
TGF-β signaling pathway can behave both as a tumor suppressor and as a tumor promoter
pathway (Derynck et al. 2001; Siegel and Massague 2003).  The tumor suppressor mechanisms
of TGF-β include, among others, its ability to inhibit cell-cycle progression as well as to induce
senescence and apoptosis (Elliott and Blobe 2005; Massague 1998).  The tumor promoting
capability of this signaling pathway, on the other hand, has been demonstrated by an increase in
invasiveness and metastatic potential of mammary neoplasms arising in transgenic mice in which
TGF-β1 or the TGF-β type I receptor are overexpressed or constitutively activated in tumor cells
(Muraoka-Cook et al. 2004; Siegel and Massague 2003; Swift et al. 2001).  Furthermore, the
concept that TGF-β signaling can facilitate tumor progression is supported by the observation
that some tumor cell lines lose their metastatic potential in xenograft systems upon disruption of
the TGF-β signaling pathway (Oft et al. 1998).  It also appears that TGF-β signaling may
promote tumor progression through effects on the tumor microenvironment by altering the
composition of the extracellular matrix or by inducing angiogenesis, as well as through direct
effects on the tumor cells by inducing Epithelial to Mesenchymal Transition (EMT) (Oft et al.
1998) or by inhibiting cell death caused by growth factor deprivation (Alazzouzi et al. 2005;
Boulay et al. 2002; Jung et al. 2006; Prehn et al. 1994; Samowitz et al. 2002; Shin et al. 2001;
Watanabe et al. 2001).  Thus, although TGF-β signaling pathway can inhibit tumor formation, it
also appears capable of paradoxically promoting invasion and metastasis in established cell lines,
especially in the context of breast cancer.
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In light of studies demonstrating both tumor suppressing and tumor promoting effects of
TGF-β, we evaluated the effect of TGF-β on the regulation of anoikis in a panel of colon cancer
cell lines that are responsive to TGF-β mediated growth inhibition (Lallemand et al. 2001;
Normanno et al. 2004; Ramachandra et al. 2002).  A panel of TGF-ß responsive cell lines was
studied to test the hypothesis that the context of the cells could affect whether the ultimate effect
of TGF-β on a cancer cell is tumor suppressing or tumor promoting.  The assessment of anoikis,
which is the induction of programmed cell death by the loss of cell anchorage on extracellular
matrix, was selected because it is one of the fundamental barriers to the metastatic and invasive
behavior of tumor cells (Frisch and Francis 1994; Frisch and Screaton 2001; Grossmann 2002).
Tumor xenograft models have shown that anoikis-resistant cancer cell lines have increased
survival in blood circulation and enhanced capacity to form metastases (Douma S et al. 2004;
Duxbury et al. 2004a; Fernandez Y et al. 2002; Zhu et al. 2001).  Of interest, we have found that
TGF-_ can have concurrent tumor promoting and tumor suppressing effects on the same cancer
cells with the ultimate effect depending on the context of the cells and presumably on the




Reagents - Luminol (cat# A8511), and p-Coumaric acid (cat# C9008) were purchased from
Sigma-Aldrich (St. Louis, MO).  The MEK1/2 inhibitor U0126 (cat# 662005), and the PI3K
inhibitor LY294002 (cat# 440204) were obtained from Calbiochem (San Diego, CA).  TGF-β1
was purchased from R&D Systems (Minneapolis, MN).  The antibodies for p-Akt (Ser473) (cat#
9271), Akt (cat# 9272), p-Erk1/2 (Thr202/Tyr204) (cat# 9101), Erk1/2 (cat# 9102), p-Smad2
(Ser465/467) (cat#3101), Smad2/3 (cat#3102), cleaved caspase3 (cat#9661), caspase3
(cat#9662), and PARP (cat#9542) were purchased from Cell Signaling (Beverly, MA).  The
antibodies for actin (cat# sc-1616), goat anti-mouse IgG-HRP (cat# SC-2005), and goat anti-
rabbit IgG-HRP (cat # SC-2004) were purchased from Santa Cruz Biotechnologies (Santa Cruz,
CA).
Cell Culture - The colon cancer cell lines HCT116, FET, Moser, GEO and CBS were generously
provided by Michael Brattain (Roswell Park Cancer Institute, Buffalo, NY).  The HCT116 plus
chromosome 3 cell line (designated HCT116+Chr3) was kindly provided by C. Richard Boland
(Baylor University Medical Center, Dallas, TX) and John Carethers (University of California
San Diego, San Diego, CA).  HCT116, HCT116+Chr3, HCT116+Chr3+DN2R, FET and Moser
were grown in Dulbecco's Modified Eagle Medium (Gibco, Grand Island, NY), and CBS and
GEO were maintained in McCoy’s 5A Medium (Sigma-Aldrich).  All media was supplemented
with 10% FBS (HyClone, Logan, UT).
7
Generation of HCT116+Chr3+DN2R - An isogenic cell line with suppressed TGFBR2 activity
was generated by transfecting the HCT116+Chr3 cell line with a plasmid expressing a dominant
negative TGFBR2 gene, pIRES-puro2-DN2R, which was constructed by cloning the DN2R
transgene, provided by Harold Moses (Vanderbilt University Medical School, Nashville, TN)
into the pIRES-puro2 vector (Clontech, Mountain View, CA). The transfection was performed
using FuGene (Roche, Indianapolis, IN) following the manufacturer’s protocol.  A pool of clones
expressing the DN2R construct was selected with 1.5µg/ml puromycin (Sigma-Aldrich) and used
in the subsequent experiments.
Thymidine incorporation assay - With the aim of evaluating cell proliferation by means of DNA
synthesis, subconfluent cells were treated with TGF-β1 (10ng/ml) in serum free conditions.
Forty-six hours after the addition of TGF-β1, 4 µCi/ml (Cook et al.)-Thymidine (Perkin Elmer,
Wellesley, MA) was added to the media.  The cells were then incubated at 37°C for an 2
additional hours.  The cells were fixed with 10% Trichloroacetic Acid (1 ml) for 30 minutes,
after which they were solubilized with 0.2N NaOH (300 µl).  Aliquots (100 µl) of the cell lysates
were resuspended in 4ml of scintillation fluid and then measured with a scintillation counter in
triplicates.
Cell Proliferation Assay:  3 x 105 cells were seeded into 6-well tissue culture plates in triplicte
and then grown for 48 hours with TGF-ß (10ng/ml) or vehicle only in serum free media.  The
cells were then harvested  and counted manually using a hemocytometer.
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3TP-lux reporter assay - In order to evaluate TGF-β-mediated transcription, tumor-derived cells
were transiently transfected with the p3TP-lux reporter (kindly provided by Joan Massagué,
Memorial Sloan-Kettering Cancer Center, New York, NY) concomitantly with the pRL-TK
reporter construct (Promega, Madison, WI).  Subsequently, the cells were treated with TGF-β1
(10ng/ml) , and luciferase activity was evaluated 48h after transfection using the Dual Luciferase
Reporter Assay System (Promega) with a Veritas luminometer (Turner Biosystems, Sunnyvale,
CA).
Anoikis Assay - For the evaluation of cell death induced by the loss of anchorage, the cells of
interest were first plated in regular cell culture vessels with FBS-containing medium at a 50%
confluence.  Twenty-four hours later, when the cells were properly attached to the plastic, the
medium was replaced with serum free media (SFM) and the cells were treated with TGF-β1
(10ng/ml).  After 48 hours, the cells were detached from the vessels and resuspended in serum-
free media.  The cells were then seeded at a concentration of 1x106 cells/ml in Ultra Low
Attachment Plates (Corning, Corning, NY), which prevent cell anchorage to the substrate, and
treated with TGF-β1 (10ng/ml) or any additional compounds as described in the studies in the
results section.  After 20 hours in suspension the occurrence of cell death was assessed by
Caspase-3 cleavage, PARP cleavage (through western blotting, protocol described below), or
DNA fragmentation analysis, ) in which the presence of nucleosomes is photometrically detected
by measuring the optical density of the samples at 405nm. (Cell Death Detection ELISA Kit,
Roche).
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Western Blotting - For evaluation of protein expression during anoikis western blotting was used.
Cells were maintained in suspension as described above, harvested, lysed with RIPA buffer
supplemented with a complete protease inhibitor cocktail (Roche) and phosphatase inhibitor
cocktails 1 and 2 (Sigma-Aldrich), and then used for SDS-PAGE.  PVDF membranes (Pierce,
Rockford, IL) were incubated with the antibodies of interest under the conditions suggested by
the maker of each antibody, and the reaction was detected by chemiluminescence using
autoradiographic methods.
Statistical analysis – All experiments were performed in triplicate and repeated at least twice.
The results in the figures are represented as means ± S.E.  The Student’s t-test was used to




TGF-β responsiveness is restored in HCT116 upon chromosome 3 transfer - The DNA mismatch
repair (MMR) deficient human colon carcinoma cell line HCT116 is resistant to TGF-β due to
biallelic mutational inactivation of TGFBR2.  An MMR proficient clone of HCT116 has been
made through the transfer of chromosome 3 into this cell line, which reconstitutes not only the
MMR gene MLH1 but also TGFBR2, restoring TGF-β responsiveness in the HCT116+Chr3 cell
line (Koi et al. 1994).  Our analysis revealed that in contrast to the parental HCT116 cell line,
HCT116+Chr3 displays TGF-_ mediated activation of the 3TP-lux reporter and is growth
inhibited by TGF-_ (Figure 1).  These results demonstrate that TGF-β sensitivity and signal
transduction is effectively restored in the HCT116+Chr3 cell line.  Moreover, given that recent
data suggest that the level of expression of TGFBR2 can affect a cell’s response to TGF-_, we
propose that this cell line is a well defined reagent for studying the effects of restoring TGF-β
signaling in TGF-_ resistant cells, because only one functional copy of TGFBR2 has been
introduced and the reconstituted TGFBR2 is in its native chromatin environment, which should
minimize spurious effects caused by overexpression of TGFBR2 (Shimanuki et al. 2007).
Although TGF-_1 inhibits proliferation in HCT116+Chr3, TGF-β1 paradoxically protects the
HCT116+Chr3 cell line from anoikis - TGF-β signaling is involved in the regulation of multiple
cellular responses disrupted during the process of tumor formation that can be potentially tumor
promoting or tumor suppressing.  After demonstrating that TGF-_ has inhibitory effects on
proliferation in HCT116+Chr3, we assessed the effect of TGF-_ on anoikis to determine whether
these effects were also consistent with tumor suppressor activities.  We chose to study anoikis
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because TGF-_ signaling has been shown to both promote and suppress anoikis in cancer cell
lines (Lallemand et al. 2001; Normanno et al. 2004).  Deregulation of anoikis is of particular
interest because it contributes to the malignant behavior of many types of neoplastic cells by
allowing anchorage-independent survival and facilitating colonization of secondary sites.  Thus,
with the aim of evaluating the effect of TGF-β1 on HCT116+Chr3 on this type of cell death,
HCT116, HCT116+Chr3, and HCT116+Chr3 transduced with a dominant negative mutant of
TGFBR2 (HCT116+Chr3+DN2R) were maintained under conditions of no attachment with or
without exogenous TGF-β1.  After twenty hours in suspension, DNA fragmentation and PARP
cleavage were evaluated using the Cell Death Detection ELISA assay and western blotting,
respectively.  Unexpectedly, we observed autocrine TGF-β1 protects HCT116+Chr3 from
anoikis and this protective influence is further enhanced by the addition of exogenous TGF-β1
(Figure 2).
TGF-β1 has varying effects on colorectal cancer cell lines that display sensitivity to TGF-_1
mediated growth inhibition – In light of our findings on the effect of TGF-_ on anoikis in the
HCT116+Chr3, we next assessed the effect of TGF-_ on anoikis in a set of TGF-_ sensitive
colorectal cancer cell lines in order to determine how commonly this phenomenon might occur in
colon cancer.  We evaluated the occurrence of cell death upon the loss of anchorage in the
human colorectal cancer lines GEO, Moser, FET and CBS through analysis of DNA
fragmentation and caspase-3 activation.  Our analysis revealed that, even though TGF-β induces
the activation of the Smad signaling pathway and inhibits proliferation in all of these cell lines,
TGF-β’s effects on anoikis in the cell lines are diverse.  We observed that although exogenous
TGF-β protects CBS from undergoing anoikis, it increases the amount of cell death in FET
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lacking anchorage.  Furthermore, we found that treatment with TGF-β  does not have a
significant effect on anoikis in GEO and Moser (Figure 3).
Smad-independent pathways are activated by exogenous TGF-β1 in HCT116+Chr3 cells when
they are in an anchorage free state - The paradoxical and varying effects of TGF-β in terms of
apoptosis regulation emphasize the relevance of the cellular context in the response of cancer
cells to this cytokine.  Since this contextual effect may be due to differences between the cell
lines with regard to post-TGF-_ receptor signal pathway activation, we studied whether
differences in the effects of TGF-_ on anoikis between the cell lines could be attributed to
differences in activation of signaling pathways by TGF-β1.  We first evaluated the PI3K/Akt
pathway in the HCT116+Chr3 cell line because this pathway has been implicated in the
protective effect of TGF-β1 against apoptosis (Shin et al. 2001).  The addition of exogenous
TGF-β1 induces AKT phosphorylation in HCT116+Chr3 grown in suspension, and inhibition of
the TGF-ß signaling pathway by the DN2R dominant negative TGFBR2 transgene inhibits AKT
phosphorylation (Figure 4A).  Additionally, we found that inhibition of autocrine TGF-β
signaling in HCT116+Chr3, by the DN2R dominant negative TGFBR2 transgene, dramatically
reduces the basal levels of phosphorylated ERK1/2, another protein associated with cell survival
(Figure 4B).
Next, we assessed whether TGF-β-induced activation of the MAPK/ERK and PI3K/AKT
pathways mediates the protective effect of TGF-_1 against anoikis.  We treated HCT116+Chr3
with the pharmacological inhibitors U0126 and LY294002 in order to block the activity of
MEK1/2 and PI3K, respectively.  Anoikis increased in HCT116+Chr3 after treatment with both
inhibitors. The increase in apoptosis was more pronounced after MAPK/ERK pathway inhibition
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compared to PI3K inhibition, and blockade of the MAPK/ERK and PI3K/AKT pathways
concurrently had an additive effect on impairing TGF-β-mediated prevention of anoikis (Figure
4C).  Interestingly, TGF-β1 could still partially prevent cell death in HCT116+Chr3 even in the
presence of both U0126 and LY294002, suggesting the existence of MEK1/2- and PI3K-
independent mechanisms in TGF-β-mediated resistance against cell death.  Treatment of
HCT116+Chr3+DN2R with LY294002 alone, or in combination with U0126, increased the
amount of cell death to a greater extent than in HCT116+Chr3 (Figure 4C).  Thus, it appears
that autocrine TGF-β signaling can partially prevent cell death after loss of anchorage even in the
presence of MEK1/2 and PI3K inhibitors.  In summary, our results suggest that even though the
activation of the PI3K/AKT and MAPK/ERK pathways is necessary for TGF-β to maximally
protect HCT116+Chr3 against anoikis, modulation of these two signaling cascades is likely not
the only mechanism through which TGF-β exerts its protective effect.
SMAD and non-SMAD pathway activation in FET, Moser, GEO and CBS and TGF-β’s effect on
anoikis - Our analysis of the expression of activated ERK1/2 and AKT showed that they are
involved in TGF-β-mediated inhibition of anoikis in HCT116+Chr3.  Consequently, we
examined the status of these pathways in other colorectal cell lines in order to determine the
specificity of TGF-β’s induction of these pathways in the setting of anoikis.  This analysis
revealed that TGF-β1 does not induce the activation of ERK1/2 or AKT in Moser or GEO
(Figure 5), which correlates with the lack of a protective effect of TGF-β1 on anoikis in these
cell lines.  Conversely, we found that although TGF-β treatment promotes anoikis in FET and
prevents it in CBS, exogenous TGF-β1 treatment induces the activation of ERK1/2 but not AKT
in these two cell lines (Figure 5).  The paradoxical observation in FET and CBS cells suggests
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then that additional signaling pathways beyond MAPK-ERK and PI3K/AKT are involved with
mediating the effect of TGF-_ on anoikis in these two colorectal cancer lines resulting in
opposing responses to TGF-β stimulation in the context of lack of anchorage.
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Discussion
Survival signals are conveyed to epithelial cells upon the activation of cell surface receptors by
components of the extracellular matrix (ECM) or by cell surface proteins of neighboring cells
(Frisch and Francis 1994).  Cell death triggered by the lack of appropriate cell-cell or cell-
extracellular matrix contacts, called anoikis, is a mechanism for maintaining tissue architecture;
and in the context of cancer progression, it represents a barrier for tumor invasion and metastasis
(Frisch and Francis 1994; Frisch and Screaton 2001; Grossmann 2002).  Tumor cells that have an
increased ability to survive in conditions of detachment appear to have an enhanced capacity to
metastasize in in vivo systems.  Tumor cells less susceptible to anoikis due to alterations in
proteins involved in integrin signaling (Duxbury et al. 2004b), cell-cell adhesion (Duxbury et al.
2004a) or the mitochondrial cell death pathway (Yawata et al. 1998) have greater metastatic
potential.
Our studies indicate that in a subset of colorectal cancer cell lines, the MAPK/ERK and
the PI3K/AKT signaling pathways can be regulated by TGF-β and that these pathways can
induce increased resistance to anoikis.  Moreover, in light of our demonstration in
HCT116+Chr3 that TGF-β inhibits cell proliferation when the cells are grown attached, we have
provided evidence that the cellular context determines the effects TGF-β exerts on colorectal
cancer lines, and that paradoxically, TGF-β can both inhibit cell growth and induce resistance to
anoikis in the same cell line.  Our results suggest then that by increasing resistance to anoikis,
TGF-β signaling may enhance the capacity of some colorectal cancer cells to invade and
colonize secondary sites.  This finding supports previous data that indicate that late-stage events
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in colorectal cancer progression may be promoted by cell-autonomous TGF-β signaling (Oft et
al. 1998).
Our results also highlight that TGF-β’s effects on tumor progression are context-dependent.
We demonstrated that even though TGF-β causes growth inhibition of HCT116+Chr3, CBS,
Moser, GEO, and FET, this cytokine induces different responses to anoikis in these colorectal
cancer lines.  It is likely that the diversity in the responses is due to the effect of concurrent
oncogene or tumor suppressor gene mutations in these cell lines even though they are all derived
from human colorectal cancers.  Accordingly, we established that TGF-β inhibits cell death upon
detachment in HCT116+Chr3 and that this protective effect is associated with the activation of
the MAPK/ERK and the PI3K/AKT pathways.  In contrast, the protective effect in CBS is
associated only with TGF-β-induced activation of MAPK/ERK.  Also, we found that exogenous
TGF-β has no effect on the occurrence of anoikis in Moser or GEO cell lines, which we propose
is related to the inability of TGF-β to modulate the activity of the MAPK/ERK or PI3K/AKT
pathways in these cell lines.
TGF-β signaling has been shown to exert a protective effect against apoptosis triggered by
different stimuli in various cell systems through a variety of molecular mechanisms.  TGF-β can
protect microglia cells from FasL-induced death by a mechanism dependent on the activity of
MEK (Schlapbach et al. 2000).  In contrast, neuronal cells are protected from apoptosis caused
by Ca2+ overloading or growth factor deprivation by TGF-β-induced upregulation of Bcl-2
expression (Prehn et al. 1994).  Furthermore, TGF-β can prevent cell death upon growth factor
withdrawal in mammary epithelial cells in an AKT-dependent fashion (Shin et al. 2001).
We now provide evidence that the MAPK/ERK and PI3K/AKT pathways are involved in
TGF-β’s effects on anoikis in colorectal cancer cell lines.  The relevance of the MAPK/ERK and
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PI3K/AKT cascades in protection against anoikis has been described in a wide variety of model
systems.  Oncogenic forms of RAS (Khwaja et al. 1997), RAF and AKT (Boisvert-Adamo and
Aplin 2006; Schulze et al. 2001) can promote resistance against anoikis in epithelial cells.  It is
also clear that the specific role of these pathways in the regulation of the protective effects is
cell-type dependent.  Furthermore, it appears that TGF-β signaling interacts with these two
survival pathways, both in Smad-dependent and Smad-independent manners, and in concert, they
can modulate the responses of tumor cells to diverse apoptotic stimuli (reviewed in (Sanchez-
Capelo 2005)).
In conclusion, our studies have revealed some of the molecular mechanisms through which
cell-autonomous TGF-β signaling may promote colon cancer progression.  Furthermore, these
studies highlight the relevance of the cellular context in the determination of the cell responses to
TGF-β stimulation.  Hence, if the TGF-β signaling pathway is to be considered for potential
therapeutic strategies, it appears likely that the cellular context of the cancer cells will need to be
taken into consideration when such treatments are developed and used clinically.
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Figure 1. TGF-β1 induces transcriptional activity of the 3TP-lux reporter construct and
growth arrest in HCT116+Chr3.  A. Parental cell line HCT116, as well as HCT116+Chr3 and
HCT116+Chr3+DN2R cells were transfected with the 3TP-lux and pRL-TK reporter constructs,
and treated with TGF-β1 (10ng/ml).  TGF-_ mediated induction of the 3TP-Lux reporter is only
apparent in the HCT116+Chr3 cell line.  B. The effect of TGF-_ on DNA synthesis was
evaluated in HCT116, HCT116+Chr3 and HCT116+Chr3+DN2R treated with TGF-β1
(10ng/ml) for 48h.  All experiments were performed in triplicate. The bars correspond to S.E.
TGF-_ suppression of thymidine incorporation is present only in the HCT116+Chr3 cell line.  C.
The effect of TGF-β on cell proliferation was assessed in HCT116, HCT116+Chr3 and
HCT116+Chr3+DN2R treated as in 2B by measuring cell counts using a hematocytometer.  All
experiments were performed in triplicate. The bars correspond to S.E.  TGF-β considerably
reduces the proliferation of HCT116+Chr3 cells. Autocrine TGF-β signaling considerably
reduces the proliferation of HCT116+Chr3 cells.  The asterisks indicate statistically significant
differences, p-value ≤ 0.05 as determined by the Student’s t-test.
Figure 2.  TGF-β1 protects HCT116+Chr3 cells from anoikis.   The cells were treated with
TGF-β1 (10ng/ml) in serum free conditions in regular tissue culture flasks.  After 48h, 1x106
cells/ml were placed in suspension in “Ultra Low Attachment Clusters” (Costar) with the same
concentration of TGF-β1.  A . DNA fragmentation was assessed with the “Cell Death Assay”
after the cells had been in suspension for twenty hours. The assays were run in triplicate. The
bars represent S.E.  The asterisks indicates a statistically significant difference, p-value ≤ 0.05 as
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determined by the Student’s t-test.  B. The expression of p-Smad-2, Smad2/3, and PARP was
evaluated in HCT116, HCT116+Chr3, and HCR116+Chr3+DN2R after 20h in suspension.
Figure 3.  Effect of TGF-β1 treatment on colorectal cancer cell lines deprived from
anchorage.  The TGF-β-responsive colon cancer cell lines FET, Moser, GEO and CBS were
treated as described in figure 2. A. Results from the Cell Death Detection ELISA assay (Roche)
demonstrate that TGF-_ induces apoptosis in FET, reduces apoptosis in CBS and has no
significant effect on GEO or Moser .  The asterisks indicate statistically significant differences,
two-tailed Student’s t-test P  ≤ 0.005.  B.  Immunoblot results for cleaved caspase 3.  These
results demonstrate similar findings compared to those from the Cell Death Detection ELISA.
and validate the findings of the ELISA assay.
Figure 4.  TGF-β-induced activation of the MAPK/ERK and PI3K/AKT pathways in
HCT116+Chr3 is necessary for protection against anoikis.  A. Western blot analysis of
phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in cells after treatment with TGF-
β1.  B. Western blot analysis of phosphorylated AKT (S473) and total AKT in cells treated with
TGF-β1. C. Cell death analysis for HCT116+Chr3 and HCT116+Chr3+DN2R deprived from
substrate for 24h and treated with LY294002 (10µM), U0126 (5µM) and TGF-β1 (10ng/ml).
These results are representative of several assays.  Each experiment was done in triplicate.  The
bars indicate S.E. The asterisks indicate statistically significant difference, p-value ≤ 0.05 as
determined by the Student’s t-test (two-tailed).
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Figure 5.  Effect of TGF-β1 treatment on caspase-3, ERK1/2, AKT and SMAD2 activation
in colorectal cancer cell lines deprived from anchorage.  Immunoblot assay results for
caspase-3, ERK1/2, AKT and SMAD2 and their active forms in FET, Moser, GEO, and CBS
maintained in suspension for 20 hours with exogenous TGF-β1 (10ng/ml) are shown.  Activation
of SMAD2 is present in all of the cell lines, but only FET and CBS display increased ERK1/2
phosphorylation after TGF-_1 treatment.





